AMRN
USDAmarin Corporation plc
Precio en Tiempo Real
Gráfico de Precios
Métricas Clave
Métricas de Mercado
Apertura
$15.670
Máximo
$15.745
Mínimo
$15.110
Volumen
0.06M
Fundamentos de la Empresa
Capitalización de Mercado
326.7M
Industria
Drug Manufacturers - General
País
Ireland
Estadísticas de Negociación
Volumen Promedio
0.10M
Bolsa
NCM
Moneda
USD
Rango de 52 Semanas
Informe de Análisis de IA
Última actualización: 5 nov 2025AMRN Analysis: Navigating Short-Term Volatility in Amarin Corporation Shares
Key Takeaways
- Recent technical indicators show bullish momentum but conflicting signals
- Q3 2025 results triggered sharp price drop, reflecting operational uncertainty
- Stock trades at historical discount to 52-week highs but risks remain
- Fundamental risks outweigh short-term value opportunities
Recent News Impact
Positive Developments
- Scientific Validation (Nov 3, 2025) New analyses presented at AHA Scientific Sessions reinforce Vascepa’s clinical data consistency and mechanism of action.
- FDA Labeling Support (Oct 27, 2025) Company publicly aligned with FDA’s fenofibrate labeling revision, potentially strengthening Vascepa’s competitive differentiation.
Mixed Earnings Release (Oct 29, 2025)
Q3 results highlighted international expansion progress but triggered a 10% single-day crash (from $18.50 to $16.70), suggesting market skepticism about execution risks in the new commercialization model.
Noticias Relacionadas
Amarin To Present New Analyses Affirming Robustness of Data from REDUCE-IT and Additional Mechanisms of Action of Eicosapentaenoic Acid (EPA) at American Heart Association (AHA) Scientific Sessions 2025
DUBLIN and BRIDGEWATER, N.J., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a company committed to advancing the science of cardiovascular care, today announced it will be presenting new
Amarin Reports Third Quarter 2025 Financial Results
Company completes transition to fully partnered commercialization model across all international markets Q3 2025 performance reflects initial impact of new approach to Europe, ongoing expansion of Rest-of-World demand,
Amarin Issues Statement Supporting FDA's Action to Revise Labeling for Fenofibrate Drugs Reinforcing a Lack of Cardiovascular Benefit
DUBLIN and BRIDGEWATER, N.J., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a company committed to advancing the science of cardiovascular care worldwide, today issued the following statement
Amarin to Report Third Quarter 2025 Financial Results and Host Conference Call on October 29, 2025
DUBLIN, Ireland and BRIDGEWATER, N.J., Oct. 15, 2025 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a company committed to advancing the science of cardiovascular care, today announced that it will report
Amarin and HLS Therapeutics Collaborate on Presenting REDUCE-IT® and EPA Mechanistic Data at the Canadian Cardiovascular Congress
DUBLIN, Ireland and BRIDGEWATER, N.J., Oct. 14, 2025 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a company committed to advancing the science of cardiovascular care, in collaboration with its Canadian
Predicción de IABeta
Recomendación de IA
Actualizado el: 10 nov 2025, 13:07
58.4% Confianza
Riesgo y Negociación
Punto de Entrada
$15.36
Toma de Ganancias
$15.93
Stop Loss
$14.06
Factores Clave
Acciones Relacionadas
TLSA
Tiziana Life Sciences Ltd. Common Shares
TCMD
Tactile Systems Technology Inc.
TNDM
Tandem Diabetes Care Inc.
AAGRW
African Agriculture Holdings Inc. Warrant
BPMC
Blueprint Medicines Corporation
Mantente Actualizado
Configura alertas de precio, recibe actualizaciones de análisis de IA y noticias de mercado en tiempo real.